Legacy Financial Advisors Inc. increased its holdings in Johnson & Johnson (NYSE:JNJ – Get Rating) by 6.3% during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 13,029 shares of the company’s stock after buying an additional 774 shares during the period. Johnson & Johnson accounts for approximately 0.5% of Legacy Financial Advisors Inc.’s portfolio, making the stock its 22nd largest holding. Legacy Financial Advisors Inc.’s holdings in Johnson & Johnson were worth $2,229,000 at the end of the most recent quarter.
Other hedge funds have also modified their holdings of the company. US Asset Management LLC purchased a new stake in shares of Johnson & Johnson in the third quarter worth $30,000. Steward Financial Group LLC purchased a new stake in shares of Johnson & Johnson in the fourth quarter worth $34,000. Jackson Wealth Management LLC increased its stake in Johnson & Johnson by 1.7% in the third quarter. Jackson Wealth Management LLC now owns 16,959 shares of the company’s stock valued at $40,000 after acquiring an additional 277 shares during the last quarter. Iron Horse Wealth Management LLC increased its stake in Johnson & Johnson by 29.9% in the fourth quarter. Iron Horse Wealth Management LLC now owns 265 shares of the company’s stock valued at $45,000 after acquiring an additional 61 shares during the last quarter. Finally, Migdal Insurance & Financial Holdings Ltd. increased its stake in Johnson & Johnson by 290.7% in the third quarter. Migdal Insurance & Financial Holdings Ltd. now owns 293 shares of the company’s stock valued at $47,000 after acquiring an additional 218 shares during the last quarter. Institutional investors own 67.84% of the company’s stock.
Johnson & Johnson stock opened at $177.66 on Tuesday. The company has a current ratio of 1.35, a quick ratio of 1.12 and a debt-to-equity ratio of 0.41. The firm has a 50-day moving average of $172.50 and a 200-day moving average of $168.01. The firm has a market cap of $467.12 billion, a P/E ratio of 22.75, a P/E/G ratio of 2.71 and a beta of 0.72. Johnson & Johnson has a 1-year low of $155.72 and a 1-year high of $184.20.
The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 7th. Stockholders of record on Tuesday, May 24th will be issued a dividend of $1.13 per share. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.06. This represents a $4.52 dividend on an annualized basis and a dividend yield of 2.54%. The ex-dividend date is Monday, May 23rd. Johnson & Johnson’s dividend payout ratio is currently 54.29%.
In other news, VP Thibaut Mongon sold 23,681 shares of the stock in a transaction dated Thursday, March 17th. The shares were sold at an average price of $176.25, for a total transaction of $4,173,776.25. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 0.35% of the company’s stock.
A number of research analysts recently commented on the company. StockNews.com assumed coverage on Johnson & Johnson in a research note on Thursday, March 31st. They issued a “strong-buy” rating on the stock. Bank of America assumed coverage on Johnson & Johnson in a research note on Wednesday, March 2nd. They issued a “neutral” rating on the stock. Morgan Stanley reduced their target price on Johnson & Johnson from $175.00 to $173.00 and set an “equal weight” rating on the stock in a research note on Wednesday, April 6th. Raymond James increased their target price on Johnson & Johnson from $185.00 to $195.00 and gave the company an “outperform” rating in a research note on Thursday, April 14th. Finally, The Goldman Sachs Group raised their price objective on Johnson & Johnson from $163.00 to $181.00 and gave the company a “neutral” rating in a research note on Tuesday, April 12th. Four analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $184.57.
Johnson & Johnson Company Profile (Get Rating)
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets.
- Get a free copy of the StockNews.com research report on Johnson & Johnson (JNJ)
- 3 No-Brainer Stocks to Buy with $1000
- Rite Aid Stock is Getting Cheap Enough to Buy Here
- Analysts Reel In Netflix Targets Ahead Of Q1 Earnings
- MarketBeat Podcast: Making Money in the Red-Hot Housing Market
- Banking On Bank Of America
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.